
Kelun-Biotech’s ADC IND for solid tumours approved in China
Kelun-Biotech’s Investigational New Drug (IND) application for SKB105 (CR-003), an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumours. In December 2025, Kelun-Biotech and Crescent Biopharma entered… Read More
